| VICORE PHARMA HOLDING AB |
| Schweden |
| Gesundheit |
| SE0007577895 / A14W4W |
| 6Y4 (Frankfurt) |
| FRA:6Y4, ETR:6Y4, 6Y4:GR |
| - |
| https://vicorepharma.com/ |
|
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company based in Sweden, specializing in the development of innovative therapies targeting severe respiratory and fibrotic diseases, particularly through angiotensin II type 2 receptor agoni..
>Volltext.. |
| 273 Mio. EUR |
| 165.57 Mio. EUR |
| 0.36 Mio. EUR |
| -42.6 Mio. EUR |
| -44.76 Mio. EUR |
| -0.19 EUR |
| - |
| 54.19 Mio. EUR |
| -35.22 Mio. EUR |
| 9.85 |
| -96.3% |
| -200.03% |
| - |
| - |
| - |
| - |
| VICORE PHARMA |
| 06.04.26 |
|